Summary
- What it does
- 5-Amino-1MQ is used as a fat-loss capsule, to lower body fat and to lift cell energy.
- How it works
- A small molecule taken as a capsule. It blocks an enzyme inside fat cells, which raises NAD+, the molecule cells use to make energy, and pushes fat cells to burn more of it.
- WADA status
- Prohibited by the World Anti-Doping Agency (WADA). Drug-tested athletes cannot use it.
5-Amino-1MQ (also known as 5-amino-1-methylquinolinium) is a performance-enhancing peptide studied for its effects on fat loss, weight loss, metabolic health. 5-Amino-1MQ is an oral NNMT inhibitor studied in rodents for fat loss and raising NAD+. No human trials; prohibited by WADA under class S0.
5-Amino-1MQ is an orally bioavailable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that consumes nicotinamide and S-adenosyl methionine to produce 1-methylnicotinamide. Blocking NNMT is intended to raise intracellular NAD+ and S-adenosyl methionine, especially in adipose tissue, where rodent work has reported increased fat-cell energy expenditure and reduced diet-induced obesity. Despite being sold and discussed alongside peptides, it is not a peptide but a methylquinolinium small molecule.
Overview
Human evidence is absent: there are no completed or active clinical trials, no regulatory approval in any jurisdiction, and every efficacy result to date comes from cell-culture or rodent models.
Because no governmental regulatory health authority has approved it for human therapeutic use, it falls under class S0 (non-approved substances) of the WADA Prohibited List, meaning 5-Amino-1MQ is prohibited by WADA at all times, both in and out of competition.
Mechanism of action
Oral small-molecule NNMT inhibitor that raises NAD+ and S-adenosyl methionine to boost fat-cell energy expenditure. Studied only in rodents for fat loss; no human trials exist.
Reported effects
Effects reported in the literature and from preclinical models include:
- Combined with a low-fat diet, the NNMT inhibitor produced dramatic whole-body adiposity and weight loss in diet-induced obese mice, rapidly normalizing those measures to age-matched lean animals. [2] Preclinical
- A low-fat diet switch alone failed to restore adiposity and body weight to age-matched control levels within the same time frame in diet-induced obese mice. [2] Preclinical
- Diet-induced obese mice treated with the NNMT inhibitor on a low-fat diet developed a distinct cecal microbiome pattern with decreased Erysipelatoclostridium and increased Lactobacillus relative abundances compared with vehicle counterparts. [2] Preclinical
- 5-Amino-1-methylquinolinium iodide significantly reduced tumor growth in urothelial bladder cancer mouse models. [1] Preclinical
- The compound enhanced the apoptotic effects of an anti-PD-L1 antibody in urothelial bladder cancer mouse models. [1] Preclinical
Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal
Natty status
5-Amino-1MQ is classified as not natty. It appears on the WADA prohibited list and is banned by major natural bodybuilding federations.[3] Use of this compound places the athlete in the enhanced category rather than the natural category in competitive contexts.
Research
The peptide has been the subject of 2 studies and reference works collected on this site.
Related compounds
Other peptides in this catalogue with overlapping mechanisms or status:
References
- a b NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. Recent
- a b c Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Recent
- a b World Anti-Doping Agency. (2026). Prohibited List 2026.
External links
- 50mg 5-Amino-1MQ — commercial
This page was last updated on September 4, 2026, at 13:11 (UTC).
Research last reviewed on September 4, 2026.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.